FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 27, Issue 1-2, 1997, Pages 93-101

  Nokes, T J C ^a,d   Johnson, S ^b   Harvey, D ^a   Goldstone, A H ^c  

^a Edgeware Hospital   (United Kingdom)

^b MUSGROVE PARK HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

FLAG; Myelodysplastic syndromes (MDS); Refractory AML; Relapsed acute myeloblastic leukaemia (AML)

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GRANULOCYTIC SARCOMA; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

EID: 0030778748     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709068275     Document Type: Article

References (15)

1. Freireich, E. (1987). Arabinosyl cytosine: A 20 year update. J. Clin. Ontol., 5, 523-524.
2. Estey, E., Plunkett, W., Dixon, D., Keating, M., McCredie, K. and Freireich, E. (1987). Variables predicting responses to high dose cytosine arabinoside therapy in patients with refractory acute leukaemia. Leukaemia, 1, 580-583.
3. Warrell, R. and Berman. E. (1986). Phase 1 & 2 study of fludarabine phosphate in leukaemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol., 4, 74-79.
4. Chun, H., Leyland-Jones, B., Caryk, S. and Hoth, D. (1986). Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rept., 70, 1225-1228.
5. Ghandi, V., Estey, E., Kemena, A., Keating, M. and Plunkett, W. (1991). Potentiation of Arabinosylcytosine triphosphate metabolism in leukaemic blasts by fludarabine monophosphate during therapy. Proc. Am. Soc. Clin. Oncol., 10, 95.
6. Estey, E., Plunkett, W., Ghandi, V., Rios, M., Kantarjian, H. and Keating, M. (1993). Fludarabine and Arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukaemia. Leukaemia and Lymphoma, 9, 343-350.
7. Estey, E., Ghandi, V., Keating, M. and Plunkett, W. (1993). G-CSF potentiates clinical and pharmacokinetic response to fludarabine and ara-C in AML and MDS. Proc. Of Asco., 12, 301.
8. Gobbi, M., Clavio, M., Miglino, M., Carrara, P., Gatti, A., Balligen, E., Cerri, P., Bruni, R., Pierri, I., Canepa, L., Vallebella, E. and Cavaliere, M. (1996). Fludarabine, Ara-C, G-CSF with or without mitoxantrone (FLANG-FLAG) are tolerable and effective in bad prognosis acute myeloid leukaemia patients. Brit. J. Haem., 93, supplement 2, 221.
9. Montillo, M., Mirto, S., Pinto, A., Tedeschi, A., Magrin, S., Zagonel, V., Leoni, P., Caroni, F., Cimino, R. and Ferrara, F. (1996). Fludarabine, arabinosylcytosine and G-CSF (FLAG) in poor risk myeloid malignancies. Brit. J. Haem., 93, supplement 2, 224.
10. Medical Research Council working party on leukaemia in adults acute myeloid leukaemia relapse trial (AML-R) (1996).
11. Keating, M., Kantarjian, H., Smith, H., Estey, E., Walters, R., Andersson, B., Beian, M. and McCredie, K. (1991). Response to salvage therapy and survival after relapse in acute myelogenous leukaemia. J. Clin. Oncol., 7, 1071-1080.
12. Archimband, E., Leblond, V., Michallet, M. et al. (1991). Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukaemia. Blood, 77, 1894-1900.
13. Geller, R., Burke, P., Karp, J. et al. (1989). A two step timed sequential treatment for acute myelocytic leukaemia. Blood, 74, 1499-1506.
14. Plunkett, W., Lilimark, J., Adams, T., Nowak, B., Estey, E., Kantarjian, H. and Keating, M. (1987). Saturation of 1-B-D-Arabinosylcytosine 5′ triphosphate accumulation in leukaemia cells during high dose 1-B-D Arabinfuranosylcytosine therapy. Cancer Research. 47, 3005-3011.
15. Al-Refaie, F., Milojkovic, D., Wong, T., Pagliuca, A., Grace, R. and Mufti, G. (1996). FLAG/Idarubicin for the treatment of poor risk myeloid malignancies. Brit. J. Haem., 93, supplement 1, 19.